Efficacy and safety of epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) monotherapy for advanced EGFR-mutated non-small cell lung cancer: systematic review and meta-analysis.
Article 2021 en
Authors
HL
Hongjoo J. Lee
GJ
Gwang Hun Jeong
HL
H. Li
Abstract
1 min read
Our systemic review indicates that EGFR-TKI therapy has improved PFS, and reduced SAEs compared to standard chemotherapy in advanced EGFR-mutated NSCLC.
Hirva Mamdani, Jeffrey Clarke, Lin Gu, Tom Stinchcombe, Jeffrey Crawford, Scott Antonia, Michael J. Campa, Andrew B. Nixon, Guru Sonpavde, George R. Simon, Neal Ready, JAMES E HERNDON, Edward F. Patz
Thibault De La Motte Rouge, Lorenzo Galluzzi, Ken A. Olaussen, Yaël Zermati, Ezgi Tasdemir, Thomas Robert, Hugues Ripoche, Vladimir Lazar, Philippe Dessen, Francis Harper, Gérard Pierron, Guillaume Pinna, Natália de Souza Araujo, Annick Harel-Belan, Jean‐Pierre Armand, Tai W. Wong, Jean Charles Soria, Guido Guido Kroemer
Thibault De La Motte Rouge, Lorenzo Galluzzi, Ken A. Olaussen, Yaël Zermati, Ezgi Tasdemir, Thomas Robert, Hugues Ripoche, Vladimir Lazar, Philippe Dessen, Francis Harper, Gérard Pierron, Guillaume Pinna, Natália M. Araujo, Annick Harel-Belan, Jean‐Pierre Armand, Tai W. Wong, Jean Charles Soria, Guido Guido Kroemer
Thibault De La Motte Rouge, Lorenzo Galluzzi, Ken A. Olaussen, Yaël Zermati, Ezgi Tasdemir, Thomas Robert, Hugues Ripoche, Vladimir Lazar, Philippe Dessen, Francis Harper, Gérard Pierron, Guillaume Pinna, Natália M. Araujo, Annick Harel-Belan, Jean‐Pierre Armand, Tai W. Wong, Jean Charles Soria, Guido Guido Kroemer
Discussion(0)
No comments yet. Be the first to comment.